Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics Inc. (NASDAQ: MYGN ) shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter 2026 financial results that included lower revenue, an operating loss, reduced full-year revenue guidance and the suspension of its adjusted EBITDA outlook. The stock closed Thursday’s regular session up 6.55% at $5.37 before falling 37.80% to $3.34 in after-hours trading. Myriad Genetics develops molecular diagnostic tests and precision medicine products that help assess disease risk and guide treatment decisions. Quarterly Results Myriad reported second-quarter revenue of $190.7 million, down 11% from a year earlier, as lower prenatal testing demand and reduced average revenue per test weighed on results. The company posted an operating loss of $38.9 million and lowered its full-year 2026 revenue guidance while suspending its adjusted EBI...
Myriad Genetics Inc. (NASDAQ: MYGN ) shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter 2026 financial results that included lower revenue, an operating loss, reduced full-year revenue guidance and the suspension of its adjusted EBITDA outlook.
The stock closed Thursday’s regular session up 6.55% at $5.37 before falling 37.80% to $3.34 in after-hours trading.
Myriad Genetics develops molecular diagnostic tests and precision medicine products that help assess disease risk and guide treatment decisions.
Quarterly Results Myriad reported second-quarter revenue of $190.7 million, down 11% from a year earlier, as lower prenatal testing demand and reduced average revenue per test weighed on results.
The company posted an operating loss of $38.9 million and lowered its full-year 2026 revenue guidance while suspending its adjusted EBITDA guidance.
Despite the weaker quarter, Myriad said its Cancer Care Continuum business continued to grow, with test volumes increasing 6% year over year.
The company also launched new products and is rolling out its “Ascend” initiative, which focuses on improving efficiency, productivity and long-term profitability. “Our second quarter 2026 performance fell short of our expectations,” CEO Sam Raha said, adding that the company is taking actions to improve reimbursement, increase efficiency and strengthen its financial performance.
Read Also: Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Trading Metrics Myriad Genetics has a market capitalization of approximately $507.19 million, with a 52-week high of $8.59 and a 52-week low of $3.53.
Over the past 12 months, MYGN shares have gained approximately 39.84%.
Edge Stock Rankings show positive price trends across the short- and medium-term time frames, while the long-term trend remains negative.
Disclaimer: This content was produced with the help of AI tools and was reviewed and published editors.
Read Also: Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move Photo Courtesy: Kumotion on Shutterstock.com